Polo-like Kinase Inhibition As a Therapeutic Target in Acute Myeloid Leukemia

Overview

Journal Oncotarget

Specialty Oncology

Date 2021 Jul 1

PMID 34194628

Citations 1

Authors

Jan Philipp Bewersdorf

Amer M Zeidan

Affiliations

Soon will be listed here.

Citing Articles

Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies.

Meyer C, Smith B, Wang J, Teuscher K, Grieb B, Howard G Proc Natl Acad Sci U S A. 2024; 121(35):e2408889121.

PMID: 39167600 PMC: 11363251. DOI: 10.1073/pnas.2408889121.

References

Bewersdorf J, Giri S, Wang R, Williams R, Tallman M, Zeidan A . Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica. 2020; 105(11):2659-2663. PMC: 7604631. DOI: 10.3324/haematol.2019.242826. View

DiNardo C, Maiti A, Rausch C, Pemmaraju N, Naqvi K, Daver N . 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020; 7(10):e724-e736. PMC: 7549397. DOI: 10.1016/S2352-3026(20)30210-6. View

Schnerch D, Schuler J, Follo M, Felthaus J, Wider D, Klingner K . Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo. Oncotarget. 2017; 8(13):21153-21166. PMC: 5400573. DOI: 10.18632/oncotarget.15503. View

Zeidan A, Ridinger M, Lin T, Becker P, Schiller G, Patel P . A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2020; 26(23):6132-6140. DOI: 10.1158/1078-0432.CCR-20-2586. View

Renner A, Dos Santos C, Recher C, Bailly C, Creancier L, Kruczynski A . Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood. 2009; 114(3):659-62. DOI: 10.1182/blood-2008-12-195867. View

DiNardo C, Jonas B, Pullarkat V, Thirman M, Garcia J, Wei A . Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020; 383(7):617-629. DOI: 10.1056/NEJMoa2012971. View

Welch J . Patterns of mutations in TP53 mutated AML. Best Pract Res Clin Haematol. 2018; 31(4):379-383. PMC: 6482955. DOI: 10.1016/j.beha.2018.09.010. View

Tontsch-Grunt U, Rudolph D, Waizenegger I, Baum A, Gerlach D, Engelhardt H . Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo. Cancer Lett. 2018; 421:112-120. DOI: 10.1016/j.canlet.2018.02.018. View

Pollyea D, Stevens B, Jones C, Winters A, Pei S, Minhajuddin M . Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018; 24(12):1859-1866. PMC: 7001730. DOI: 10.1038/s41591-018-0233-1. View

10.

Goroshchuk O, Kolosenko I, Vidarsdottir L, Azimi A, Palm-Apergi C . Polo-like kinases and acute leukemia. Oncogene. 2018; 38(1):1-16. DOI: 10.1038/s41388-018-0443-5. View

11.

Shallis R, Wang R, Davidoff A, Ma X, Zeidan A . Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019; 36:70-87. DOI: 10.1016/j.blre.2019.04.005. View

12.

Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D . NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012; 11(4):1006-16. DOI: 10.1158/1535-7163.MCT-11-0765. View

13.

Perl A, Martinelli G, Cortes J, Neubauer A, Berman E, Paolini S . Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. N Engl J Med. 2019; 381(18):1728-1740. DOI: 10.1056/NEJMoa1902688. View

14.

Barr F, Sillje H, Nigg E . Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol. 2004; 5(6):429-40. DOI: 10.1038/nrm1401. View

15.

Dohner H, Lubbert M, Fiedler W, Fouillard L, Haaland A, Brandwein J . Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014; 124(9):1426-33. PMC: 4148765. DOI: 10.1182/blood-2014-03-560557. View

16.

Ferrara F, Lessi F, Vitagliano O, Birkenghi E, Rossi G . Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia. Cancers (Basel). 2019; 11(2). PMC: 6406399. DOI: 10.3390/cancers11020224. View

17.

Ley T, Miller C, Ding L, Raphael B, Mungall A, Robertson A . Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368(22):2059-74. PMC: 3767041. DOI: 10.1056/NEJMoa1301689. View

18.

Stein E, DiNardo C, Pollyea D, Fathi A, Roboz G, Altman J . Enasidenib in mutant relapsed or refractory acute myeloid leukemia. Blood. 2017; 130(6):722-731. PMC: 5572791. DOI: 10.1182/blood-2017-04-779405. View

19.

Rudolph D, Impagnatiello M, Blaukopf C, Sommer C, Gerlich D, Roth M . Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia. J Pharmacol Exp Ther. 2015; 352(3):579-89. DOI: 10.1124/jpet.114.221150. View

20.

Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S . The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013; 8(3):e58424. PMC: 3592825. DOI: 10.1371/journal.pone.0058424. View